Evidence map›Paper›PMID 35860565›Full record

ArticleFrontiers in oncology2022

β-Hydroxyisovaleryl-Shikonin Exerts an Antitumor Effect on Pancreatic Cancer Through the PI3K/AKT Signaling Pathway.

Yu Zeng, Haifeng Zhang, Minghui Zhu, Qingfan Pu, Jinhai Li, Xiao Hu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yu ZengDepartment of Hepatobiliary Surgery, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Haifeng ZhangDepartment of Hepatobiliary Surgery, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Minghui ZhuDepartment of Hepatobiliary Surgery, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Qingfan PuDepartment of Hepatobiliary Surgery, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Jinhai LiDepartment of Hepatobiliary Surgery, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xiao HuDepartment of Hepatobiliary Surgery, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Ruian People's Hospital · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PC) is marked with a low survival rate and lack of recognized effective treatment strategy. We investigated the antitumor effect of β-hydroxyisovaleryl-shikonin (β-HIVS) on PC and the associated working mechanism. Cell toxicity was determined using Cell Counting Kit-8 (CCK-8) assay. Acridine Orange/Ethidium Bromide (AO/EB) double-fluorescent staining assay accompanied by flow cytometry was utilized to estimate cell apoptosis. Cell cycle, reactive oxygen species (ROS), and mitochondrial membrane potential were all evaluated using flow cytometry. Transwell and wound healing assays were performed to evaluate cell migration and invasion. Protein expression was analyzed by Western blots. A xenograft mouse model was employed to determine the antitumor effect of β-HIVS

Indexed as

antitumor effectapoptosispancreatic cancerPI3K/AKTβ-hydroxyisovaleryl-shikonin

Identifiers

PMID35860565
PMCPMC9293047
OpenAlexW4283803831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.